Retrospective Analysis of Short-Term Responses to PRP Injections for Patients With Vocal Fold Scars and Presbylaryngis.

Vocal fold scarring and presbylarynx significantly impair voice quality, leading to a decline in patients' quality of life. These pathologies represent considerable challenges for laryngologists. Traditional treatments often produce suboptimal outcomes. Platelet-rich plasma (PRP) is an innovative, minimally invasive treatment that uses autologous biological material rich in growth factors and platelets, with positive effects on tissue regeneration and repair. Based on its promising effects, we started using PRP as a therapeutic option in vocal folds scars and presbylarynx. We performed a retrospective study on the efficacy and clinical outcomes of PRP injections performed in these patients. Between October 2021 and November 2023, 48 patients (35 women, 13 men; mean age 53 ± 15 years) were treated with PRP for a total of 109 injections for acute or chronic vocal fold lesions or presbylaryngis. PRP preparation followed a standardized protocol. The mean volume of PRP injected per vocal fold was 0.57 ± 0.30 mL, with high platelet purity (95.05% ± 3.48) found in PRP biological characterization. No adverse events were reported. The vocal outcomes assessed 1 month after the treatment found no modification in the acoustic parameters, but a significant improvement in the perceptual voice analysis on the G (P < 0.001), R (P = 0.005), and B (P = 0.008) of the GRB scale, and a clinical improvement on videolaryngostroboscopy for 62.5% of the patients. Most importantly, 70.8% of the patients reported subjective improvement with an average reduction in VHI-30 score of 10.79 points, with 32% of patients achieving clinically significant improvement (≥18 points). PRP injections demonstrate promising efficacy and safety in vocal fold scars and presbylaryngis treatment, with a significant improvement in perceptual voice analysis and subjective assessments. Further studies with larger cohorts and control groups are needed to confirm these findings and optimize PRP therapy protocols.